E-Greetings from the Allergy Advocacy Association

February, 2019

Love is in the air during February with Valentine’s Day and National Heart Month, while we continue our endeavors to keep everyone safe and healthy. We have several upcoming events for which you will want to mark your calendar. First is an excellent support group, FACTS, for any parent with children who have life-threatening allergies:

Food Allergies Coping Teaching Supporting (FACTS) meeting
Fairport United Methodist Church
31 West Church Street, Fairport, NY 14450
Saturday, March 16th from 10 am – noon
Contact: Joy Leinenbach, co-founder
This email address is being protected from spambots. You need JavaScript enabled to view it.
585-748-5961

On April 1, 2019, your Allergy Advocacy Association will be presenting an Epi Near You NY training seminar at the University of Rochester’s School of Nursing. Dr. Kirsi Jarvinen-Seppo, Chief of Pediatric Allergy and Immunology at the UR Medical Center, will be presenting. We had over 100 people attend our last seminar at St. John Fisher, so be sure to RSVP soon. Admission is free and you will have an opportunity to ask questions from one of Rochester’s leading experts on severe allergies:

Epi Near You New York training seminar
University of Rochester
School of Nursing
Auditorium (1-304)
255 Crittenden Boulevard
Rochester, NY  14620
Monday, April 1st, 2019 7pm
RSVP to This email address is being protected from spambots. You need JavaScript enabled to view it.
or call 585-255-0384
FREE admission!

Lastly we will be making our annual trek to Albany for a Food Allergy Awareness Day. It’s a great opportunity to speak with our state legislators in person about upcoming legislation, (see Article 1 below) and all are welcome to join us:

Food Allergy Awareness Day
Legislative Office Building
NYS Capitol Albany, NY
Wednesday, May 15th, 2019 9am – 2pm
Exhibit Location: Glass doors at the LOB entrance on the Concourse level

Now Is the Time for Generic Epinephrine in New York State

If you carry an Epi-Pen, you are likely very much aware of the worldwide shortage of epinephrine since November of 2017. The price has also been skyrocketing. The upside is that this has brought more competition into the marketplace, as well as an effort to pass legislation permitting a generic to be substituted by a pharmacist whenever a patient is prescribed a brand name EAI device. Unless the doctor notes the prescription must be “dispensed as written,” a generic could be easily dispensed as long as it is the same dosage and strength and contains the same active ingredients. Read here about current efforts to get this legislation passed and other alternatives to the Mylan Epi-Pen.

Now Is the Time for Generic Epinephrine in New York State

text

February 14th, 2019
By Jon Terry

Greetings. Concerning the New York State legislature and the 2019 session, recent developments have encouraged the Allergy Advocacy Association in our ongoing efforts to improve access to life-saving epinephrine for all individuals with life-threatening allergies. Those developments include substitution of generic drugs for brand-name medications. If new laws are enacted encouraging the use of generics by patients and consumers, lives will almost certainly be saved.

Continue Reading

DBV Technologies Sets Sights on FDA Resubmission for Peanut Allergy Treatment

Good news! DBV Technologies is preparing to resubmit their application to the Food and Drug Administration (FDA) for a new treatment for peanut allergies in children called Viaskin Peanut, better known as the peanut patch. The company has obtained Fast Track and Breakthrough Therapy designation from the FDA and is planning to submit by the third quarter of this year, a faster than expected timeframe. Meanwhile, rival Aimmune Therapeutics has already submitted their application and may win U.S. approval for its drug ahead of DBV.

DBV Technologies Sets Sights on FDA Resubmission for Peanut Allergy Treatment

Opened peanut shells with peanuts

By Ned Pagliarulo
Feb. 14, 2019

Dive Brief:

DBV Technologies expects to resubmit its experimental treatment for peanut allergy to the Food and Drug Administration by the third quarter of this year, a speedier-than-expected path back to the regulator after the company withdrew its original application last December. 

Continue Reading

StellaPharma to Develop Epinephrine Nasal Spray Product

No one particularly likes needles, including the person administering them and the person receiving medication with them—even in an emergency. So we are pleased to report efforts are being made to develop a dry powder nasal spray of epinephrine to treat anaphylaxis. The Food and Drug Administration (FDA) has already stated that nasal delivery can be an excellent alternative for delivery of rescue medications during life threatening patient events, such as drug overdoses.

StellaPharma to Develop Epinephrine Nasal Spray Product

Young woman using epinephrine nasal spray

News provided by
StellaPharma, Inc.
Jan 15, 2019
RALEIGH, N.C.
PRNewswire

StellaPharma, Inc. (Stella) announced today that it has entered into an agreement whereby Stella will acquire the assets of G2B Pharma (G2B) including IP related to a dry powder nasal formulation of epinephrine being developed for anaphylaxis. Recent U.S. FDA product approvals indicate nasal delivery can be an excellent alternative route for delivery of rescue medications during life threatening patient events.

Continue Reading

Food Allergy-Related Insurance Claims Up in Almost Every State in the Country

One measure of the increasing number of allergies in the U.S. is how many health insurance claims have been filed for anaphylaxis food reactions. A recent study showed that claims rose a whopping 377% from 2007 to 2016! The Food Allergy Research & Education (FARE) group recently launched the Contains: Courage campaign, to drive awareness and raise an unprecedented amount of funding for research, therapies and diagnostics to improve the quality of life of children and adults who are affected.

Food Allergy-Related Insurance Claims Up in Almost Every State in the Country

Health Benefits Claim Form

By News Wire
January 23rd, 2019

McLean, VA – Food Allergy Research & Education (FARE), the largest private funder of food allergy research in the world, today released the results of a study on private insurance claim lines and food allergies. The study showed that claim lines with diagnoses of anaphylactic food reactions rose 377% from 2007 to 2016, and in every state except Massachusetts, claim lines with anaphylactic food reactions and history of food allergy diagnoses represented an increasing share of all medical claim lines from 2009 to 2016. Anaphylaxis is a serious allergic reaction that can occur quickly and is potentially life-threatening.  

Continue Reading